Biopharmaceutical company Sinovac Biotech Ltd (NASDAQ:SVA) stated on Tuesday that it recorded a loss to common shareholders of USD7.4m ( USD0.07 per basic and diluted share) for the first quarter ended 31 March 2020.
This marks a dip in earnings when compared with net income to common shareholders of USD1.2m (USD0.01 per basic and diluted share) in the same period of the previous year.
Sales of USD15.4m were recorded for the first quarter of 2020, down 57.9% from sale of USD36.6m in the first quarter of 2019.
While operating expenses decreased, net income attributable to common shareholders was impacted by the decrease in sales.
R&D expenses of USD5.7m were reported in the first quarter of 2020, a rise versus R&D of USD4.5m in the prior year period, as it continued to invest in its product pipeline including sIPV and PPV, as well as the research and development of the COVID-19 vaccine.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients